TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17400821

Group type: EXPERIMENTAL
Intervention: Chamomile
Number of subjects: 0
Study: 15125911

Group type: EXPERIMENTAL
Intervention: Postural threat condition (greatest vs. least)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Older adults (OA) under postural threat
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Younger adults (YA) under postural threat
Number of subjects: 32
Study: 11528359

Group type: COMPARATOR
Intervention: Red clover extracts
Number of subjects: 5
Study: 9779695

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 32
Study: 7803885

Group type: EXPERIMENTAL
Intervention: Histamine2-receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic agents (general)
Number of subjects: 0
Study: 2928038

Group type: EXPERIMENTAL
Intervention: Opaque, sealed bottle containing sugar
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control bottle containing sand
Number of subjects: 50
Study: 4311189

Group type: EXPERIMENTAL
Intervention: Depot tetracosactrin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corticotrophin gel
Number of subjects: 12
Study: 31196231

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28407811

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Balanced crystalloids (Lactated Ringer's or Plasma‐Lyte A©)
Number of subjects: 15000
Study: 25837207

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 24
Study: 23453871

Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 881
Study: 21205385

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (FS)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Ferric pyrophosphate (FPP)
Number of subjects: 258
Study: 18056791

Group type: EXPERIMENTAL
Intervention: EAA+CHO
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 16442045

Group type: EXPERIMENTAL
Intervention: Laser lipolysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser lipolysis followed by biweekly treatments with the Tri-active system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 15896584

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12538199

Group type: EXPERIMENTAL
Intervention: Epidural morphine (3.5-5 mg) plus ketamine (20/30 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Epidural morphine (3.5-5 mg)
Number of subjects: 104
Study: 10396749

Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 10 units (group H)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 5 units (group M)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 1 unit (group L)
Number of subjects: 41
Study: 7564134

Group type: EXPERIMENTAL
Intervention: Healon with 20 seconds removal time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healon with 40 seconds removal time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healon GV with 20 seconds removal time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healon GV with 40 seconds removal time
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 40
Study: 2405653

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) cephalothin (250 mg/L) and tobramycin (8 mg/L)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg loading followed by 300 mg daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin (400 mg followed by 300 mg daily) and rifampicin (300 mg daily)
Number of subjects: 39
Study: 6252744

Group type: EXPERIMENTAL
Intervention: FK 33-824 (0.5 mg im)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naloxone (4 mg iv)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lysine vasopressin (5 IU im)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31227978

Group type: EXPERIMENTAL
Intervention: Capsule debridement during CIED replacement
Number of subjects: 773

Group type: COMPARATOR
Intervention: No capsule debridement during CIED replacement
Number of subjects: 773
Study: 29353712

Group type: EXPERIMENTAL
Intervention: Nurse-led collaborative care intervention
Number of subjects: 325

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 325
Study: 26898519

Group type: EXPERIMENTAL
Intervention: Virtual planning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional planning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 24117002

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 μg of potassium iodide daily) - Group A
Number of subjects: 365

Group type: COMPARATOR
Intervention: No iodine supplementation - Group B
Number of subjects: 365
Study: 22431865

Group type: EXPERIMENTAL
Intervention: PG guidance using either PG-1 or PG-2 algorithms
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: PG-2 algorithm
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: PG guidance
Number of subjects: 2370
Study: 21091414

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions including daily supervised, progressive exercises until discharge and a postoperative exercise booklet on discharge
Number of subjects: 76
Study: 19066757

Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 581

Group type: COMPARATOR
Intervention: Aliskiren 300 mg
Number of subjects: 581

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 17283532

Group type: EXPERIMENTAL
Intervention: KAI1 positive group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: nm23 positive group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ETS-1 positive group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: VEGF positive group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Common expression of KAI1 and nm23
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Common expression of ETS-1 and VEGF
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Expressions of KAI1, nm23, ETS-1, and VEGF proteins
Number of subjects: 110
Study: 14560825

Group type: EXPERIMENTAL
Intervention: 3 cannulated cancellous lag screws
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2 cannulated cancellous lag screws
Number of subjects: 10
Study: 10793604

Group type: EXPERIMENTAL
Intervention: Warm air sensation at 40 +/- 0.2 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold sensation from ethyl chloride spray
Number of subjects: 30
Study: 8619185

Group type: EXPERIMENTAL
Intervention: Dacron patch angioplasty
Number of subjects: 190

Group type: COMPARATOR
Intervention: Vein patch angioplasty
Number of subjects: 190
Study: 1428035

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Famotidine 40 mg once daily
Number of subjects: 129
Study: 6399250

Group type: EXPERIMENTAL
Intervention: Drugs
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31014267

Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity treadmill walking
Number of subjects: 27

Group type: COMPARATOR
Intervention: 30 min of seated rest
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) split (≥45 min average daily MVPA)
Number of subjects: 27
Study: 29756474

Group type: EXPERIMENTAL
Intervention: Henna applied with 15 cm extent on the patients' sacrum along with standard prevention cares for decubitus ulcers.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard prevention cares for decubitus ulcers (Control group).
Number of subjects: 80
Study: 27987595

Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy (TRT) (45 Gy/30 fractions)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy (TRT) (42 Gy/15 fractions)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: First chemotherapy-course
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Reduction in SOD
Number of subjects: 157
Study: 24745024

Group type: EXPERIMENTAL
Intervention: Reinforced feedback in virtual environment (RFVE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR)
Number of subjects: 44
Study: 22266545

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 14

Group type: COMPARATOR
Intervention: Quiet sitting
Number of subjects: 14
Study: 20522615

Group type: EXPERIMENTAL
Intervention: Low dose (LD) pantoprazole (0.3 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium dose (MD) pantoprazole (0.6 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose (HD) pantoprazole (1.2 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium dose (MD) pantoprazole (0.6 mg/kg) for EE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose (HD) pantoprazole (1.2 mg/kg) for EE
Number of subjects: 60
Study: 18847151

Group type: EXPERIMENTAL
Intervention: Nebulized steroid fluticasone (Flixotide Nebules)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined treatment (nebulized fluticasone and intravenous methylprednisolone)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Flixotide treatment arm
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study: 15971087

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tramadol + Midazolam (TM)
Number of subjects: 35
Study: 12962188

Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 24
Study: 10599358

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8747045

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 43
Study: 2106256

Group type: EXPERIMENTAL
Intervention: [1-13C]acetate infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: [2-13C]acetate infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: [1-13C]acetate infusion during exogenous glucose infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: [2-13C]acetate infusion during exogenous glucose infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: [1-14C]acetate infusion
Number of subjects: 10
Study: 7030373

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and propranolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propranolol (50% dosage reduction)
Number of subjects: 25
Study: 30789934

Group type: EXPERIMENTAL
Intervention: Motivational patient education including motivational communication techniques and repeated training until correct administration.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard feedback on erroneous administration steps without further assessment or reinforced training.
Number of subjects: 91
Study: 30193275

Group type: EXPERIMENTAL
Intervention: Immediate reduction to 0.4 mg of nicotine per gram of tobacco cigarettes
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual reduction from 15.5 mg to 0.4 mg of nicotine per gram of tobacco cigarettes
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control group (maintenance on 15.5 mg of nicotine per gram of tobacco cigarettes)
Number of subjects: 1250
Study: 26797774

Group type: EXPERIMENTAL
Intervention: Low dose betahistine (2 × 24 mg daily)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High dose betahistine (3 × 48 mg daily)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 221
Study: 24060491

Group type: EXPERIMENTAL
Intervention: Arm cranking exercise (12-week program, 3 sessions per week)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study: 23018292

Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spirometric parameters
Number of subjects: 40
Study: 19811927

Group type: EXPERIMENTAL
Intervention: MHSACP technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Moderately hypothermic open heart procedures (control group)
Number of subjects: 50
Study: 16890485

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16257815

Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg oral solution
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo oral solution
Number of subjects: 454
Study: 12170051

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 10499773

Group type: EXPERIMENTAL
Intervention: TA 1200 (1200 mg of thioctic acid)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: TA 600 (600 mg of thioctic acid)
Number of subjects: 65

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 65
Study: 8688994

Group type: COMPARATOR
Intervention: Reference formulation (R)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test formulation (T)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DHECT with metabolites
Number of subjects: 12
Study: 1924625

Group type: EXPERIMENTAL
Intervention: Active marijuana (0.8% THC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Active marijuana (3.6% THC)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo marijuana (0.0% THC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fasting (24 hr)
Number of subjects: 5
Study: 7050949

Group type: EXPERIMENTAL
Intervention: Ciclazindol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ciclazindol vs Placebo
Number of subjects: 114
Study: 28810393

Group type: EXPERIMENTAL
Intervention: Dove Evolution commercial
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Specific disclaimer labels
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Generic disclaimer labels
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Follow-up after 2 weeks
Number of subjects: 287
Study: 29414757

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME)
Number of subjects: 200
Study: 27227739

Group type: EXPERIMENTAL
Intervention: LPV/r-based ART
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-ART
Number of subjects: 45
Study: 24461499

Group type: EXPERIMENTAL
Intervention: Thin-flap LASIK in thin-cornea group
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (CCT ≥500 μm)
Number of subjects: 291
Study: 22794528

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (children who were never in foster care)
Number of subjects: 0
Study: 21130379

Group type: EXPERIMENTAL
Intervention: Pulmonary Index Score (PIS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: National Asthma Council Guidelines (NACG)
Number of subjects: 65
Study: 17621203

Group type: EXPERIMENTAL
Intervention: Active exercise and education using a cognitive behavioral therapy (CBT) approach, delivered in eight 2-hour group sessions over 6 weeks by physiotherapists.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Educational booklet and audio-cassette (provided to both intervention and control groups).
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Patients who expressed a preference for the intervention.
Number of subjects: 196
Study: 15848558

Group type: EXPERIMENTAL
Intervention: 0.75 g MMF twice a day with SRL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1 g MMF twice a day with SRL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5 g MMF twice a day with SRL
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1 g MMF twice a day with CsA
Number of subjects: 27
Study: 12364424

Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 6 days starting on the day of RAI therapy (G2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 19 days starting on the day of MMI withdrawal (G3)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RAI alone (G1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 6 days (G2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 19 days (G3)
Number of subjects: 36
Study: 11803607

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with 0.6 g of protein and 35 kcal/kg/day, recombinant human erythropoietin (rHuEPO) at a dose of 40 U kg/week, and keto acids (KA) 100 mg/kg/day (Group I)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-protein diet (LPD) and recombinant human erythropoietin (rHuEPO) (Group II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-protein diet (LPD) only (Group III)
Number of subjects: 105
Study: 9667297

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 2.5 microg/ml fentanyl
Number of subjects: 138

Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone
Number of subjects: 138
Study: 7906809

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 9364

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 9364
Study: 2459541

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 120
Study: 5356547

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study: 517720

Group type: EXPERIMENTAL
Intervention: Ethamsylate 1000 mg intravenously before induction of anaesthesia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 30620642

Group type: EXPERIMENTAL
Intervention: CHO intake algorithm based on CGM trends
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard exercise guidelines (0.5 g CHO/kg/h when glucose <8 mmol/L)
Number of subjects: 14
Study: 29540273

Group type: COMPARATOR
Intervention: Usual diet and placebo pills (n = 29)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Usual diet and antioxidant supplements (n = 29)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods closely matched to antioxidant content of supplements and placebo (n = 30)
Number of subjects: 88
Study: 27334799

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg (noncarriers)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 mg/kg (noncarriers)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab 0.5 mg/kg (noncarriers)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab 1.0 mg/kg (noncarriers)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab (0.5 mg/kg)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab (1.0 mg/kg)
Number of subjects: 694
Study: 24554074

Group type: EXPERIMENTAL
Intervention: Hybrid CAS and coronary bypass surgery (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concomitant carotid and coronary surgery (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 23075680

Group type: EXPERIMENTAL
Intervention: Pemetrexed combined with cisplatin (PP group)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin (GP group)
Number of subjects: 251
Study: 19861383

Group type: EXPERIMENTAL
Intervention: Positive culture from generator pocket
Number of subjects: 122

Group type: COMPARATOR
Intervention: Negative culture from generator pocket
Number of subjects: 122
Study: 16714366

Group type: EXPERIMENTAL
Intervention: Internet group received health and health‐behavior assessment, tailored feedback on health and health behavior (specifically fruit consumption), and an online referral to see a physician/nurse if necessary.
Number of subjects: 1071

Group type: COMPARATOR
Intervention: P&P group received the same assessment, preprinted generic advice on fruit consumption and a mailed referral (where applicable).
Number of subjects: 1071
Study: 16253185

Group type: EXPERIMENTAL
Intervention: Face-to-face guidance in early healthcare for children at home with a pamphlet developed by WHO as teaching material
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without receiving guidance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Face-to-face guidance in early healthcare for children at home
Number of subjects: 100
Study: 11911557

Group type: EXPERIMENTAL
Intervention: 5-day gatifloxacin 400 mg once daily
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: 10-day gatifloxacin 400 mg once daily
Number of subjects: 445

Group type: COMPARATOR
Intervention: 10-day amoxicillin/clavulanate 875 mg twice daily
Number of subjects: 445
Study: 10419989

Group type: EXPERIMENTAL
Intervention: Dark green, leafy vegetables with fat (10 g/100 g)
Number of subjects: 519